Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer（IDEAL Stage 2b）

DFS is defined as the time from the date of surgery to the date of first documented tumor recurrence, metastasis, or death from any cause.

DFS is defined as the time from the date of surgery to the date of first documented tumor recurrence, metastasis, or death from any cause.

OS is defined as the time from the date of surgery to death from any cause.

OS is defined as the time from the date of surgery to death from any cause.

RFS is defined as the time from the date of surgery to the first occurrence of disease recurrence.

RFS is defined as the time from the date of surgery to the first occurrence of disease recurrence.

DSS is defined as the length of time that the patients survived from the time of randomization or treatment initiation until death from the specific disease in question.

DSS is defined as the length of time that the patients survived from the time of randomization or treatment initiation until death from the specific disease in question

PFS is defined as the time from the date of surgery to the first occurrence of either disease progression or death from any cause. Disease progression includes recurrence, metastasis, or progression of residual disease.

PFS is defined as the time from the date of surgery to the first occurrence of either disease progression or death from any cause. Disease progression includes recurrence, metastasis, or progression of residual disease.

All-cause mortality occurring within 30 days after surgery.

Postoperative complications occurring within 30 days will be recorded, including bleeding, perforation, lymphatic leakage, respiratory complications, cardiovascular complications, anastomotic fistula, according to the Clavien-Dindo scale

Rate of unscheduled reoperation within 30 days after the initial surgery

Rate of unplanned hospital readmission within 30 days after discharge following the initial surgery

Proportion of patients with no residual tumor microscopically confirmed on both the primary tumor resection margins and resected lymph nodes, assessed by postoperative pathological examination.

Proportion of patients requiring additional surgical procedures due to intraoperative or postoperative pathological findings

Estimated total volume of blood loss during the surgical procedure

Total number of days from the date of surgery to hospital discharge

Average number of days from the date of surgery to hospital discharge

It is evaluated by gastric emptying half-time (GET₁/₂) measured via radionuclide scintigraphy.

Time from the date of surgery to the first passage of flatus, indicating recovery of gastrointestinal motility.

It is a combined score based on serum albumin level and total lymphocyte count. It is calculated as 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (cells/μL). Higher scores indicate better nutritional and immunological status.

Proportion of participants with any of the following adverse findings on surveillance endoscopy: poor anastomotic healing, residual lesions, metachronous lesions, or local recurrence. Participants are counted once if they meet any of these criteria.

Proportion of participants with any of the following adverse findings on contrast-enhanced CT of the chest, abdomen, and pelvis: local recurrence, distant metastasis, or abnormal lymph nodes.

Proportion of participants with positive findings for malignancy on histopathological examination of biopsy specimens obtained during scheduled follow-up endoscopy or additional surgery.

The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30(EORTC-QLQ-C30) includes 30 items measuring functional, symptomatic, and global quality-of-life domains. Scores are transformed to a 0-100 scale, with higher scores indicating better quality of life.

The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Module 22(EORTC-QLQ-STO22) supplement contains 22 items assessing symptoms and concerns specific to gastric cancer. Scores are transformed to a 0-100 scale, with higher scores indicating greater symptom burden.

The Postgastrectomy Syndrome Assessment Scale 45(PGSAS-45), consisting of 45 items, will be used to comprehensively evaluate postgastrectomy symptoms, digestive status, and daily life functions. All subscale scores are linearly transformed to a 0-100 range. For symptom-related subscales, higher scores indicate greater symptom burden; for functional and quality of life subscales, higher scores indicate better functioning or quality of life.